Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is listed today as Werewolf Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2020 | $72 M | No. 2 | $50 to $250 million | equity | SEC | |
| Aug 2019 | $56 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Werewolf Therapeutics, Inc., its revenue in fiscal 2024 came from these business segments: Reportable $1.88 million.
Annual report (SEC XBRL) · Dec 2024
Werewolf Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).
SEC Form D · Jan 2021
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2021
Products and services#
No products or services of Werewolf Therapeutics, Inc. are on record.
Investors#
26 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arkin Bio Ventures 2 L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Arkin Bio Ventures GPGP Ltd. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| HBM Healthcare Investments (Cayman) Ltd. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longwood Fund III GP, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longwood Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM Asset Management Investors BV2014 LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM Bioimpact LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM BioVentures 2014 (B), L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM BioVentures 2014 GP LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM BioVentures 2014 LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM BioVentures 2014, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM Oncology Impact Management GP LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM Oncology Innovations Fund GP LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| MPM Oncology Innovations Fund LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Oncology Impact Fund (Cayman) Management L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Sphera Funds Management LTD. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sphera Global Healthcare GP Ltd. | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sphera Global Healthcare Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Taiho Ventures LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| UBS Oncology Impact Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Upmc | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.
Largest shareholders today
Institutions holding Werewolf Therapeutics, Inc. shares, as of Sep 30, 2026.
- Balyasny Asset Management L.P.$3 M6.26%
- ADAR1 Capital Management, LLC$2 M4.16%
- Vanguard Capital Management LLC$1 M2.51%
- Lynx1 Capital Management LP$1 M1.35%
- Sphera Funds Management LTD.$1 M1.29%
- DC Funds, LP$1 M1.21%
- Jane Street Group, LLC$1 M1.16%
- Citadel Advisors LLC$1 M1.14%
- Renaissance Technologies LLC$1 M1.13%
- HRT Financial LP$0 M0.85%
- Geode Capital Management, LLC$0 M0.84%
- Acadian Asset Management LLC$0 M0.65%
- Vanguard Fiduciary Trust Co$0 M0.55%
- XTX Topco Ltd$0 M0.43%
- Bank Of America Corp /de/$0 M0.35%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel Hicklin | Executive officer | Jan 2021 |
| David Cordo | Executive officer | Jan 2021 |
| Alon Lazarus | Director | Jan 2021 |
| Briggs Morrison | Director | Jan 2021 |
| Daniel Hicklin | Director | Jan 2021 |
| Derek DiRocco | Director | Jan 2021 |
| Elise Wang | Director | Jan 2021 |
| Luke Evnin | Director | Jan 2021 |
| Sakae Asanuma | Director | Jan 2021 |
| Christoph Westphal | Director | Aug 2020 |
| Patrick Baeuerle | Director | Aug 2019 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.